Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

TCR targeting hematopoiesis to cure leukemia

J. H. Frederik Falkenburg, Mirjam H. M. Heemskerk

Blood (2024) 144 (10): 1031–1033.

https://doi.org/10.1182/blood.2024024972

Published: 2024

Journal Articles

Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens

Kyra J. Fuchs, Marian van de Meent, M. Willy Honders, Indu Khatri, Michel G. D. Kester, Eva A. S. Koster, Georgia Koutsoumpli, Arnoud H. de Ru, Cornelis A. M. van Bergen, Peter A. van Veelen, Peter A. C. ’t Hoen, Peter van Balen, Erik B. van den Akker, J. Hendrik Veelken, Constantijn J. M. Halkes, J. H. Frederik Falkenburg, Marieke Griffioen

Blood (2024) 143 (18): 1856–1872.

https://doi.org/10.1182/blood.2023022343

Published: 2024

Includes: Supplemental data

Journal Articles

Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM

Thuja Meurer, Pietro Crivello, Maximilian Metzing, Michel Kester, Dominik A. Megger, Weiqiang Chen, Peter A. van Veelen, Peter van Balen, Astrid M. Westendorf, Georg Homa, Sophia E. Layer, Amin T. Turki, Marieke Griffioen, Peter A. Horn, Barbara Sitek, Dietrich W. Beelen, J. H. Frederik Falkenburg, Esteban Arrieta-Bolaños, Katharina Fleischhauer

Blood (2021) 137 (7): 923–928.

https://doi.org/10.1182/blood.2020008464

Published: 2021

Includes: Supplemental data

Journal Articles

A minority of T cells recognizing tumor-associated antigens presented in self-HLA can provoke antitumor reactivity

Marthe C. J. Roex, Lois Hageman, Sabrina A. J. Veld, Esther van Egmond, Conny Hoogstraten, Christian Stemberger, Lothar Germeroth, Hermann Einsele, J. H. Frederik Falkenburg, Inge Jedema

Blood (2020) 136 (4): 455–467.

https://doi.org/10.1182/blood.2019004443

Published: 2020

Includes: Supplemental data

Journal Articles

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1

Lorenz Jahn, Pleun Hombrink, Renate S. Hagedoorn, Michel G. D. Kester, Dirk M. van der Steen, Tania Rodriguez, Tsvetelina Pentcheva-Hoang, Arnoud H. de Ru, Marjolein P. Schoonakker, Miranda H. Meeuwsen, Marieke Griffioen, Peter A. van Veelen, J. H. Frederik Falkenburg, Mirjam H. M. Heemskerk

Blood (2017) 129 (10): 1284–1295.

https://doi.org/10.1182/blood-2016-09-737536

Published: 2017

Includes: Supplemental data

Journal Articles

CD4 + T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation

Cor H. J. Lamers, Rebecca Wijers, Cornelis A. M. van Bergen, Judith A. E. Somers, Eric Braakman, Jan Willem Gratama, Reno Debets, J. H. Frederik Falkenburg, Jan J. Cornelissen

Blood (2016) 128 (17): 2165–2174.

https://doi.org/10.1182/blood-2016-06-718619

Published: 2016

Includes: Supplemental data

Journal Articles

Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b

Lorenz Jahn, Pleun Hombrink, Chopie Hassan, Michel G. D. Kester, Dirk M. van der Steen, Renate S. Hagedoorn, J. H. Frederik Falkenburg, Peter A. van Veelen, Mirjam H. M. Heemskerk

Blood (2015) 125 (6): 949–958.

https://doi.org/10.1182/blood-2014-07-587840

Published: 2015

Includes: Supplemental data

Journal Articles

Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy

Anniek B. van der Waart, Noortje M. P. van de Weem, Frans Maas, Cynthia S. M. Kramer, Michel G. D. Kester, J. H. Frederik Falkenburg, Nicolaas Schaap, Joop H. Jansen, Robbert van der Voort, Luca Gattinoni, Willemijn Hobo, Harry Dolstra

Blood (2014) 124 (23): 3490–3500.

https://doi.org/10.1182/blood-2014-05-578583

Published: 2014

Includes: Supplemental data

Journal Articles

HLA class II upregulation during viral infection leads to HLA-DP–directed graft-versus-host disease after CD4+ donor lymphocyte infusion

Sanja Stevanović, Cornelis A. M. van Bergen, Simone A. P. van Luxemburg-Heijs, Boris van der Zouwen, Ekaterina S. Jordanova, Alwine B. Kruisselbrink, Marian van de Meent, Jessica C. Harskamp, Frans H. J. Claas, Erik W. A. Marijt, Jaap Jan Zwaginga, Constantijn J. M. Halkes, Inge Jedema, Marieke Griffioen, J. H. Frederik Falkenburg

Blood (2013) 122 (11): 1963–1973.

https://doi.org/10.1182/blood-2012-12-470872

Published: 2013

Includes: Supplemental data

Journal Articles

Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO

Anita N. Kremer, Edith D. van der Meijden, Maria W. Honders, Jelle J. Goeman, Emmanuel J. H. J. Wiertz, J. H. Frederik Falkenburg, Marieke Griffioen

Blood (2012) 120 (16): 3246–3255.

https://doi.org/10.1182/blood-2011-12-399311

Published: 2012

Includes: Supplemental data

Journal Articles

Allo-HLA–reactive T cells inducing graft-versus-host disease are single peptide specific

Avital L. Amir, Dirk M. van der Steen, Renate S. Hagedoorn, Michel G. D. Kester, Cornelis A. M. van Bergen, Jan W. Drijfhout, Arnoud H. de Ru, J. H. Frederik Falkenburg, Peter A. van Veelen, Mirjam H. M. Heemskerk

Blood (2011) 118 (26): 6733–6742.

https://doi.org/10.1182/blood-2011-05-354787

Published: 2011

Journal Articles

PR1 on the edge of humoral immunotherapy

J. H. Frederik Falkenburg

Blood (2011) 117 (16): 4164–4165.

https://doi.org/10.1182/blood-2011-03-335943

Published: 2011

Journal Articles

A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL

Bart A. Nijmeijer, Marianke L. J. van Schie, Constantijn J. M. Halkes, Marieke Griffioen, Roelof Willemze, J. H. Frederik Falkenburg

Blood (2010) 116 (26): 5930–5940.

https://doi.org/10.1182/blood-2010-01-262006

Published: 2010

Journal Articles

Combating cancer with allogeneic T cells

J. H. Frederik Falkenburg

Blood (2010) 115 (19): 3856–3857.

https://doi.org/10.1182/blood-2010-02-267328

Published: 2010

Journal Articles

Allo-HLA reactivity of virus-specific memory T cells is common

Avital L. Amir, Lloyd J. A. D'Orsogna, Dave L. Roelen, Marleen M. van Loenen, Renate S. Hagedoorn, Renate de Boer, Menno A. W. G. van der Hoorn, Michel G. D. Kester, Ilias I. N. Doxiadis, J. H. Frederik Falkenburg, Frans H. J. Claas, Mirjam H. M. Heemskerk

Blood (2010) 115 (15): 3146–3157.

https://doi.org/10.1182/blood-2009-07-234906

Published: 2010

Journal Articles

Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro

Caroline E. Rutten, Simone A. P. van Luxemburg-Heijs, Edith D. van der Meijden, Marieke Griffioen, Machteld Oudshoorn, Roel Willemze, J. H. Frederik Falkenburg

Blood (2010) 115 (1): 151–153.

https://doi.org/10.1182/blood-2009-10-249821

Published: 2010

Journal Articles

Identification of 4 new HLA-DR–restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity

Anita N. Stumpf, Edith D. van der Meijden, Cornelis A. M. van Bergen, Roel Willemze, J. H. Frederik Falkenburg, Marieke Griffioen

Blood (2009) 114 (17): 3684–3692.

https://doi.org/10.1182/blood-2009-03-208017

Published: 2009

Journal Articles

Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1–reactive cytotoxic T cells

Wieger J. Norde, Ingrid M. Overes, Frans Maas, Hanny Fredrix, Johanna C. M. Vos, Michel G. D. Kester, Robbert van der Voort, Inge Jedema, J. H. Frederik Falkenburg, Anton V. Schattenberg, Theo M. de Witte, Harry Dolstra

Blood (2009) 113 (10): 2312–2323.

https://doi.org/10.1182/blood-2008-04-153825

Published: 2009

Includes: Supplemental data

Journal Articles

Multiple myeloma–reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene

Cornelis A. M. van Bergen, Michel G. D. Kester, Inge Jedema, Mirjam H. M. Heemskerk, Simone A. P. van Luxemburg-Heijs, Freke M. Kloosterboer, W. A. Erik Marijt, Arnoud H. de Ru, M. Ron Schaafsma, Roel Willemze, Peter A. van Veelen, J. H. Frederik Falkenburg

Blood (2007) 109 (9): 4089–4096.

https://doi.org/10.1182/blood-2006-08-043935

Published: 2007

Journal Articles

Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex

Mirjam H. M. Heemskerk, Renate S. Hagedoorn, Menno A. W. G. van der Hoorn, Lars T. van der Veken, Manja Hoogeboom, Michel G. D. Kester, Roel Willemze, J. H. Frederik Falkenburg

Blood (2006) 109 (1): 235–243.

https://doi.org/10.1182/blood-2006-03-013318

Published: 2006

NARROW

TCR targeting hematopoiesis to cure leukemia

Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens

Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM

A minority of T cells recognizing tumor-associated antigens presented in self-HLA can provoke antitumor reactivity

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1

CD4 + T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation

Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b

Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy

HLA class II upregulation during viral infection leads to HLA-DP–directed graft-versus-host disease after CD4+ donor lymphocyte infusion

Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO

Allo-HLA–reactive T cells inducing graft-versus-host disease are single peptide specific

PR1 on the edge of humoral immunotherapy

A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL

Combating cancer with allogeneic T cells

Allo-HLA reactivity of virus-specific memory T cells is common

Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro

Identification of 4 new HLA-DR–restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity

Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1–reactive cytotoxic T cells

Multiple myeloma–reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene

Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only